Prosecution Insights
Last updated: April 19, 2026

Examiner: PALLAY, MICHAEL B

Tech Center 1600 • Art Units: 1617 1645

This examiner grants 56% of resolved cases

Performance Statistics

56.0%
Allow Rate
-4.0% vs TC avg
766
Total Applications
+35.0%
Interview Lift
1203
Avg Prosecution Days
Based on 707 resolved cases, 2023–2026

Rejection Statute Breakdown

1.5%
§101 Eligibility
13.2%
§102 Novelty
46.2%
§103 Obviousness
23.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17793755 NOVEL ADDITIVES FOR AGROCHEMICAL FORMULATIONS Non-Final OA BASF SE
19301132 OPHTHALMOLOGICAL COMPOSITIONS AND METHODS OF USE THEREOF Non-Final OA PS Therapy, Inc.
18295520 CONTACT LENS COMPOSITIONS AND METHODS OF USE THEREOF Non-Final OA PS Therapy, Inc.
18251343 COATED COMPOSITIONS OF BIOLOGICALLY ACTIVE INGREDIENTS FOR ORAL ADMINISTRATION TO RUMINANTS Non-Final OA Evonik Operations GmbH
18128271 SOLID DEODORIZER FOR CONCEALING A VISUAL INDICATOR ASSOCIATED WITH PRODUCT LIFE SIGNAL Final Rejection The Procter & Gamble Company
17834994 ORAL PRODUCT WITH SUSTAINED FLAVOR RELEASE Non-Final OA NICOVENTURES TRADING LIMITED
17765540 METHODS OF CONTROLLING OR PREVENTING INFESTATION OF BANANA PLANTS BY PHYTOPATHOGENIC MICROORGANISMS OF THE GENUS PSEUDOCERCOSPORA Non-Final OA SYNGENTA CROP PROTECTION AG
17624161 SELECTIVE WEED CONTROL Final Rejection SYNGENTA CROP PROTECTION AG
18068598 OCULAR TREATMENT COMPOSITIONS AND METHODS Non-Final OA The Johns Hopkins University
17927704 An Adhesive Laminate for Application to Skin Final Rejection Coloplast A/S
16921366 COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE Final Rejection University of Virginia Patent Foundation
16007041 AUXIN HERBICIDAL MIXTURES Final Rejection Monsanto Technology LLC
18579096 TARGETED GLYCOSAMINOGLYCAN-PARTICLES AND METHODS OF USE Non-Final OA The Board of Regents of the University of Oklahoma
17195819 PIGMENT COMPOSITION FOR SEED COATINGS Final Rejection Sun Chemical Corporation
17996084 METHODS OF DECREASING MUSCLE ATROPHY AND/OR PROMOTING MUSCLE REGENERATION Non-Final OA ABBOTT LABORATORIES
18551766 SUBSTITUTED PYRROLIDIN-2-ONES, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES Non-Final OA Bayer Aktiengesellschaft
17627221 HERBICIDAL COMPOSITION CONTAINING R-TYPE PYRIDYLOXY CARBOXYLIC ACID DERIVATIVE AND USE THEREOF Final Rejection Qingdao Kingagroot Chemical Compound Co., Ltd.
18641369 DIHYDROMYRICETIN NANOEMULSION FORMULATIONS AND METHODS FOR FORMING THEM Final Rejection The Trustees of Princeton University
18651700 USE OF HIGHER ALIPHATIC ALCOHOL IN IMPROVING NITROGEN FIXING CAPACITY AND DROUGHT RESISTANCE CAPACITY OF LEGUMES Non-Final OA Zhuhai Runnong Science and Technology Co. Ltd
18703265 WATER REDUCED COMPACT CONDITIONER COMPOSITION Non-Final OA WELLA GERMANY GMBH
18592784 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI Non-Final OA RedHill Biopharma Ltd.
18266870 USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME Non-Final OA CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD
18386327 GOLD NANO-DELIVERY SYSTEM FOR PAIN AND CANCER THERAPY Non-Final OA Toronto Poly Clinic Inc.
18453429 Premoistened Wipes with Virucidal Properties Against Non-Enveloped Viruses Non-Final OA ARXADA, LLC
18257605 ANTIOXIDANT NUTRITIONAL SUPPLEMENT FOR IMMUNE SYSTEM SUPPORT Non-Final OA VIVA NATURALS, INC.
18206895 Brain Targeted Nutritional Therapeutic for Improved Cognitive Function and Treatment of Mild Cognitive Impairment Non-Final OA BRAINCARE LLC
18326585 BANDING SOLUTION FOR MANUFACTURING ENTERIC HARD CAPSULES AND ENTERIC HARD CAPSULE MANUFACTURED USING THE SAME Non-Final OA SUHEUNG CO., LTD.
18140414 WOUND-CLEANSING PAD APPARATUS AND METHODS OF USE Non-Final OA Farrow Medtech, LLC
18248925 Hybrid Micro Molding-Fiber Deposition Substrate Processing for Cell Biology Manipulation and Local Anisotropy Final Rejection Ri.MED FOUNDATION
18158156 HAEMOSTATIC MATERIAL Non-Final OA Medtrade Products Limited

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month